Daily Stock Analysis, DBX, DBV TECHNOLOGIES SA-SPON ADR, priceseries

DBV TECHNOLOGIES SA-SPON ADR. Daily Stock Analysis
Stock Information
Open
18.14
Close
18.27
High
18.46
Low
18.08
Previous Close
18.06
Daily Price Gain
0.21
YTD High
26.49
YTD High Date
Feb 20, 2019
YTD Low
17.20
YTD Low Date
Aug 15, 2019
YTD Price Change
-2.40
YTD Gain
-11.61%
52 Week High
26.49
52 Week High Date
Feb 20, 2019
52 Week Low
17.20
52 Week Low Date
Aug 15, 2019
52 Week Price Change
-3.24
52 Week Gain
-15.06%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2019
21.28
Jan 29. 2019
23.26
16 Trading Days
9.32%
Link
LONG
Sep 4. 2019
18.38
Sep 23. 2019
20.15
13 Trading Days
9.62%
Link
Company Information
Stock Symbol
DBX
Exchange
NASDAQ
Company URL
http://www.dbv-technologies.com
Company Phone
33(0)155427878
CEO
Pierre-Henri Benhamou
Headquarters
-
Business Address
177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE, FRANCE 92120
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001613780
About

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. The company focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients. It has designed two products candidates: Viaskin Peanut and Viaskin Milk. DBV Technologies was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Description

DBV Technologies S.A. is engaged in the research, development, and marketing of products for the diagnosis and treatment of allergies, primarily food allergies in young children. The company provides Diallertest, a non-invasive patch allergy diagnostic for infants, children, or adults for the diagnosis of allergy in cow milk, wheat, and soybean. Its products include Viaskin Peanut, an immunotherapy product for the treatment of patients with peanut allergies; Viaskin Milk, for the treatment of CMPA and eosinophilic esophagitis, as well as food polyallergies; and Viaskin House Dust Mite, a mite desensitization product for the treatment of mite allergy. The company was founded in 2002 and is based in Bagneux, France.